Difficulty: Medium
Average Score: 82%
Practice
Indicate the organophosphate cholinesterase inhibitor, which can be made up in an aqueous solution for ophthalmic use and retains its activity within a week:
Correct answer
C
Rationale
In this scenario, the correct answer is C) Echothiophate. Echothiophate is the organophosphate cholinesterase inhibitor that can be made up in an aqueous solution for ophthalmic use and retains its activity within a week.
Echothiophate is specifically designed for ophthalmic use due to its ability to penetrate the eye tissues and exert its cholinesterase inhibitory effects locally. This makes it an effective option for treating conditions such as glaucoma by reducing intraocular pressure.
Analyzing the other options:
A) Polypso-6-num: This is a fictitious name and not a known medication, making it an incorrect choice.
B) Edrophonium: Edrophonium is a short-acting reversible cholinesterase inhibitor used for diagnostic purposes in conditions like myasthenia gravis. It is not formulated for ophthalmic use.
D) Neostigmine: Neostigmine is primarily used to treat myasthenia gravis and is not typically formulated for ophthalmic use.
Educational context:
Understanding the pharmacological properties of different cholinesterase inhibitors is crucial for healthcare professionals, especially in pharmacology across the lifespan. Knowing the specific characteristics of each medication allows for safe and effective administration based on the patient's needs and the intended route of administration. This knowledge helps in selecting the most appropriate medication for a given clinical situation, ensuring optimal patient outcomes.
Echothiophate is specifically designed for ophthalmic use due to its ability to penetrate the eye tissues and exert its cholinesterase inhibitory effects locally. This makes it an effective option for treating conditions such as glaucoma by reducing intraocular pressure.
Analyzing the other options:
A) Polypso-6-num: This is a fictitious name and not a known medication, making it an incorrect choice.
B) Edrophonium: Edrophonium is a short-acting reversible cholinesterase inhibitor used for diagnostic purposes in conditions like myasthenia gravis. It is not formulated for ophthalmic use.
D) Neostigmine: Neostigmine is primarily used to treat myasthenia gravis and is not typically formulated for ophthalmic use.
Educational context:
Understanding the pharmacological properties of different cholinesterase inhibitors is crucial for healthcare professionals, especially in pharmacology across the lifespan. Knowing the specific characteristics of each medication allows for safe and effective administration based on the patient's needs and the intended route of administration. This knowledge helps in selecting the most appropriate medication for a given clinical situation, ensuring optimal patient outcomes.